Skip to main content

Table 1 Model parameters values and references: base case and sensitivity analysis

From: Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain

  Base case Sensitivity analysis References
Parameter   Lower limit Upper limit  
Kidney cancer incidence 40+ (per 100,000) 19.8 17.82 21.78 [22]
RCC incidence (over kidney cancer incidence) 90% 85% 95% [24, 25]
RCC incidence at diagnosis (over RCC incidence) 20% 15% 25% [24, 25]
RCC mortality (localized disease) 1.66% 1.49% 1.83% [23]
Transition to advanced RCC (year 1) 13.18% 11.86% 14.49% [20]
Transition to advanced RCC (years 2 and 3) 4.57% 4.11% 5.02% [20]
Transition to advanced RCC (years 4 and 5) 1.92% 1.73% 2.11% [20]
Transition to advanced RCC (year 6 and 7) 1.64% 1.48% 1.81% [20]
Transition to advanced RCC (year 8 to 10) 1.26% 1.13% 1.38% [20]
Advanced RCC of favorable or intermediate risk 89% 80.1% 97.9% [26]
Transition to post-advanced RCC 100%    [7, 13]